SKIP TO CONTENT
About Abbott
Contact
International | eng
Country Language

CARDIOVASCULAR

International | eng
Country Language

Esprit™ BTK

Everolimus Eluting Resorbable Scaffold

Esprit BTK
LIFE-BTK Study

Pioneering a new standard of care for BTK treatment.

The Esprit™ BTK System is a breakthrough innovation, pioneering a new standard of care by delivering superior efficacy***, without the drawbacks of traditional therapies2

Superior Results, Without Compromising Safety

  • Superior efficacy vs balloon angioplasty (74.5% vs 43.7%), demonstrating a 30.8% improvement in limb salvage and primary patency at 1 year2
  • Demonstrated to be as safe as PTA† in the landmark LIFE-BTK randomized controlled trial2
     

Proven Durability & Performance

  • Proven durability in CLTI patients, with a low target lesion reintervention rate* of 6.5% at 1 year1
  • Demonstrated reduction in disease progression for CLTI patients vs balloon angioplasty, with consistent performance (limb salvage and primary patency) across a range of lesion lengths up to 148mm5,**
     

Designed for Today and the Future

  • Designed to address vessel recoil and dissection1, with radial strength similar to a metallic stent within the first 6 months7
  • Sustained everolimus elution to inhibit restenosis and maximize patency8
  • Completely resorbable scaffold offering flexibility for the future6
     

This device is commercially available for use in select international markets. Check the regulatory status in your geography.

 

References

† Primary Safety Endpoint is Freedom from Major Adverse Limb Event (6 mo) + Peri-operative Death (30 days)
*Results reported as CD-TLR within 1 year
**Data from lesion length terciles post hoc analysis
***Primary efficacy endpoint is a composite of limb salvage and primary patency at 1 year

  1. Esprit™ BTK Everolimus Eluting Resorbable Scaffold System Instructions for Use (IFU).
  2. Varcoe, R. Primary Outcomes of the Esprit™ BTK Drug-Eluting Resorbable Scaffold for the Treatment of Infrapopliteal Lesions: The LIFE-BTK Trial. Presented at TCT 2023.
  3. Parikh, S. LIFE-BTK: The Top Line Results and Beyond. Presented at TCT 2023.
  4. Varcoe, RL., et al. Drug-Eluting Resorbable Scaffold versus Angioplasty for Infrapopliteal Artery Disease. N Engl J Med 2024; 390:9-19.
  5. Varcoe, RL., et al. Drug-Eluting Resorbable Scaffold versus Angioplasty for Infrapopliteal Artery Disease. N Engl J Med 2024; 390:9-19. Supplementary Appendix.
  6. Data on File. Excluding platinum markers
  7. Data on File. Testing done with Xience Sierra 3.5 x 38mm at nominal
  8. Data on File.

MAT-2405960 v1.0

POLICIES & ADVISORIES
HEALTHCARE PROFESSIONALS
PATIENTS & CAREGIVERS
Abbott logo

Information contained herein for distribution outside the U.S. only.

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

© 2024 Abbott. All Rights Reserved.

MAT-2001111 v7.0

Disclaimer

You are about to enter an Abbott country- or region-specific website. 

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions

Do you wish to continue and enter this website? 

YES

MAT-2305078 v1.0